Clinical trials: Oligodendroglioma
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
This phase I trial studies the side effects and best dose of carcinoembryonic antigen-expressing measles virus (MV-CEA) in treating patients with glioblastoma multiforme that has come back.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Recurrent Glioblastoma
- Trial name
- NCT00390299
- Testing
- Carcinoembryonic Antigen-Expressing Measles Virus, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Glioma, Pilocytic Astrocytoma
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics…
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT02372409
- Testing
- MRI-guided laser ablation, Doxorubicin, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive).
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00823797
- Testing
- Bendamustine Hydrochloride, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma.
- Trial name
- NCT00631137
- Testing
- testosterone gel applied to skin, whey powder protein
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
High Grade Gliomas, including anaplastic astrocytomas, anaplastic oligodendrogliomas and glioblastomas (GBM), are the most common and most aggressive primary brain tumors.
- Conditions
- Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)
- Trial name
- NCT01663012
- Testing
- Etirinotecan pegol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Lawrence Recht
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114140
- Testing
- Temozolomide, Radiation therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Radiation Therapy Oncology Group
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma
- Trial name
- NCT02175745
- Testing
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Erik Mittra
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Brain and Central Nervous System Tumors
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00058123
- Testing
- poly ICLC
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Astrocytoma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
- Trial name
- NCT00575887
- Testing
- Temozolomide
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Marmara University
Glioblastoma, Adult-type Diffuse Gliomas
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating…
- Trial name
- FIGHT-209 (NCT05267106)
- Testing
- Pemigatinib
- Where
- 79 sites in United States, Denmark and 7 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00499473
- Testing
- sunitinib malate, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma.
- Conditions
- Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma
- Trial name
- NCT01462695
- Testing
- Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
- Where
- 96 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Brain Tumors
Antineoplaston Therapy in Treating Children With Brain Tumors
RATIONALE: Current therapies for childhood brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors.
- Trial name
- NCT00003458
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Burzynski Research Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01478321
- Testing
- Temozolomide, hypofractionated radiation therapy, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Northwestern University
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc
Glioblastoma, Gliosarcoma
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- AXL1717 (NCT01721577)
- Testing
- AXL1717
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center